Want to join the conversation?
$MYL's Meda acquisition is expected to deliver estimated growth through 2018 of about 3% in revenues and about 5% in adjusted EBITDA. On a 2015 combined basis, the company will go from having two-thirds of the revenue from Generics and Specialty business will represent more than a third of the business.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)